Prevalence of dyslipidemia in statin-treated patients in Canada: Results of the DYSlipidemia International Study (DYSIS)

被引:45
作者
Goodman, Shaun G. [1 ,2 ,3 ]
Langer, Anatoly [2 ,3 ]
Bastien, Natacha R. [4 ]
McPherson, Ruth [5 ]
Francis, Gordon A. [6 ]
Genest, Jacques J., Jr. [7 ]
Leiter, Lawrence A. [2 ]
机构
[1] St Michaels Hosp, Div Cardiol, Toronto, ON M5B 1W8, Canada
[2] Univ Toronto, Toronto, ON M5S 1A1, Canada
[3] Canadian Heart Res Ctr, Toronto, ON, Canada
[4] Merck Frosst Canada Ltd, Kirkland, PQ, Canada
[5] Univ Ottawa, Inst Heart, Ottawa, ON, Canada
[6] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada
[7] McGill Univ, Montreal, PQ, Canada
关键词
Cholesterol; Dyslipidemia; Lipids; HIGH-RISK; MANAGEMENT; PREVENTION; GUIDELINES; DIAGNOSIS;
D O I
10.1016/S0828-282X(10)70454-2
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
BACKGROUND: Despite clear guideline recommendations, there is a growing body of evidence that there is suboptimal use of lipid-lowering treatment in Canadians. OBJECTIVE: To assess the prevalence and types of persistent lipid abnormalities in Canadian patients receiving statin therapy. METHODS: The present cross-sectional study recruited 2436 outpatients 45 years of age or older who were treated with statins by 232 physicians from 10 provinces; all underwent clinical examination and had their latest fasting lipid values while on statin therapy recorded. RESULTS: The median patient age was 66 years (interquartile range [IQR] 58 to 74 years), 60% were men and 80% were in the high 10-year risk category. The median low-density lipoprotein cholesterol level was 2.0 mmol/L (IQR 1.6 mmol/L to 2.5 mmol/L) and the median total cholesterol/high-density lipoprotein cholesterol ratio was 3.4 mmol/L (IQR 2.8 mmol/L to 4.1 mmol/L). However, based on the 2006 Canadian Cardiovascular Society recommendations, 37% of all patients did not have a low-density lipoprotein cholesterol level at goal or intervention target level, including 45% of high-risk category patients. The majority of patients received atorvastatin (50%) or rosuvastatin (37%) but primarily at low-to-medium doses, and a minority (14%) received additional lipid-modifying therapies. CONCLUSIONS: The present observational study highlights the need for more intensive treatment of lipid abnormalities, particularly among high-risk patients. Recognizing several important limitations related to the observational nature of the study, the findings suggest the possibility that, in addition to optimizing adherence, there remains an important need to titrate current statin therapy to higher doses and potentially use a combination of lipid-modifying treatments (once the statin dose has been truly maximized) to further bridge the gap between evidence-based medicine and current Canadian practice.
引用
收藏
页码:E330 / E335
页数:6
相关论文
共 13 条
[1]
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins [J].
Baigent, C ;
Keech, A ;
Kearney, PM ;
Blackwell, L ;
Buck, G ;
Pollicino, C ;
Kirby, A ;
Sourjina, T ;
Peto, R ;
Collins, R ;
Simes, J .
LANCET, 2005, 366 (9493) :1267-1278
[2]
Results of the National Cholesterol Education (NCEP) Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations [J].
Davidson, MH ;
Maki, KC ;
Pearson, TA ;
Pasternak, RC ;
Deedwania, PC ;
McKenney, JM ;
Fonarow, GC ;
Maron, DJ ;
Ansell, BJ ;
Clark, LT ;
Ballantyne, CM .
AMERICAN JOURNAL OF CARDIOLOGY, 2005, 96 (04) :556-563
[3]
2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult-2009 recommendations [J].
Genest, Jacques ;
McPherson, Ruth ;
Frohlich, Jiri ;
Anderson, Todd ;
Campbell, Norm ;
Carpentier, Andre ;
Couture, Patrick ;
Dufour, Robert ;
Fodor, George ;
Francis, Gordon A. ;
Grover, Steven ;
Gupta, Milan ;
Hegele, Robert A. ;
Lau, David C. ;
Leiter, Lawrence ;
Lewis, Gary F. ;
Lonn, Eva ;
Mancini, G. B. John ;
Ng, Dominic ;
Pearson, Glen J. ;
Sniderman, Allan ;
Stone, James A. ;
Ur, Ehud .
CANADIAN JOURNAL OF CARDIOLOGY, 2009, 25 (10) :567-579
[4]
Gitt AK, 2009, EUR HEART J, V30, P303
[5]
How many cardiovascular events can be prevented with optimal management of high-risk Canadians? [J].
Grima, Daniel T. ;
Leiter, Lawrence A. ;
Goodman, Shaun G. ;
Attard, Cheryl L. ;
Chow, Chi-Ming ;
Langer, Anatoly .
CANADIAN JOURNAL OF CARDIOLOGY, 2008, 24 (05) :363-368
[6]
Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report [J].
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, R ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Cleeman, JI ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ ;
Keller, SA ;
Jehle, AJ .
CIRCULATION, 2002, 106 (25) :3143-3421
[7]
Leiter LA, 2008, J FAM PRACTICE, V57, P661
[8]
Canadian Cardiovascular Society position statement - Recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease [J].
McPherson, Ruth ;
Frohlich, Jiri ;
Fodor, George ;
Genest, Jacques .
CANADIAN JOURNAL OF CARDIOLOGY, 2006, 22 (11) :913-927
[9]
Opportunity for intervention to achieve American Heart Association guidelines for optimal lipid levels in high-risk women in a managed care setting [J].
Mosca, L ;
Merz, NB ;
Blumenthal, RS ;
Cziraky, MJ ;
Fabunmi, RP ;
Sarawate, C ;
Watson, KE ;
Willey, VJ ;
Stanek, EJ .
CIRCULATION, 2005, 111 (04) :488-493
[10]
The Lipid Treatment Assessment Project (L-TAP) -: A multicenter survey to evaluate the percentages of dyslipidemic, patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals [J].
Pearson, TA ;
Laurora, I ;
Chu, H ;
Kafonek, S .
ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (04) :459-467